Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 75
Initiation of PIONEER trials for oral semaglutide
2016
PIONEER 3: vs sitagliptin
78 weeks, n=1,860
PIONEER 1: monotherapy
26 weeks, n=704
PIONEER 2: vs empagliflozin
52 weeks, n=816
2017
2018
PIONEER 4: vs liraglutide
52 weeks, n=690
PIONEER 5: moderate renal impairment
26 weeks, n=324
PIONEER 6: cardiovascular outcomes
Event driven (>122 MACE), n=3,176
PIONEER 7: flexible dose escalation
52 weeks, n=500
PIONEER 8: insulin add-on
26+26 weeks, n=720
PIONEER 9: JAPAN monotherapy
52 weeks, n=230
PIONEER 10: JAPAN OAD combination
52 weeks, n=336
Note: Preliminary estimated timing of trials from first patient first visit (FPFV) to last patient last visit (LPLV), n = approximate number of randomised people; MACE: Major Cardiovascular Events;
OAD: oral anti-diabetic
changing
diabetes®
novo nordiskView entire presentation